|
A strategic cooperation agreement on innovative drug research and development (r&d) was signed between Shanghai Medical Group Co., Ltd. (601607. SH, hereinafter referred to as SMG) and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as FDZJ) on 23rd, February, 2011. SMG and FDZJ will carry out an all-around collaboration on r&d and industrialization of four projects including r – higher affinity TNF receptor block, r – human lymphomtoxin derivatives (LT)， vincristin lipsome (LVCR)，duteporfen and so on. Through this opportunity of the collaboration and based on the r&d results accumulated for many years, FDZJ will gain more technical breakthroughs and achieve commercial and industrial value of the projects on these three r & d fields of genetic engineering drugs, lipsome drugs and photodynamic drugs.
Please refer the public announcement issued by FDZJ for details.
 |
沪ICP备10027510号-1